Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | PLK1 | P53350 | 8/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95456 | 0.88 | NPC1 (0.58) | HDAC8HDAC6HDAC2HPGDTSHR | |
| SCHEMBL250247 | 0.87 | HDAC6 (0.80) | HDAC8HDAC6HDAC2HPGDTSHR | |
| SCHEMBL2538888 | 0.80 | PLK1 (0.68) | HDAC8HDAC6HDAC2HPGDTSHR | |
| SCHEMBL14115137 | 0.80 | HDAC6 (0.70) | HDAC8HDAC6HDAC2HPGDTSHR | |
| SCHEMBL16198923 | 0.80 | HDAC6 (0.70) | HDAC8HDAC6HDAC2HPGDTSHR | |
| SCHEMBL27960135 | 0.80 | PLAU (0.62) | HDAC8HDAC6HDAC2HPGDTSHR | |
| SCHEMBL8237229 | 0.79 | HDAC8 (0.61) | HDAC8HDAC6HDAC2HPGDTSHR | |
| SCHEMBL23933223 | 0.78 | HDAC8 (0.67) | HDAC8HDAC6HDAC2HPGDTSHR | |
| SCHEMBL19631295 | 0.78 | HDAC6 (1.00) | HDAC8HDAC6HDAC2HPGDTSHR | |
| SCHEMBL2643668 | 0.78 | HDAC8 (0.67) | HDAC8HDAC6HDAC2HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113004278-B | Bicyclic heterocycles as FGFR inhibitors | 因赛特控股公司 | 2023-07-21 | — | — | CN | claimed |
| CN-113004278-A | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2021-06-22 | — | — | CN | claimed |
| CN-107438607-B | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2021-02-05 | — | — | CN | claimed |
| EP-2629777-B1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-12-19 | — | — | EP | claimed |
| US-20170253582-A1 | TRIAZOLE MODIFIED COUMARIN AND BIPHENYL AMIDE-BASED HSP90 INHIBITORS | REATA PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | claimed |
| EP-3154964-A1 | TRIAZOLE MODIFIED COUMARIN AND BIPHENYL AMIDE-BASED HSP90 INHIBITORS | The University of Kansas (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2015192099-A1 | TRIAZOLE MODIFIED COUMARIN AND BIPHENYL AMIDE-BASED HSP90 INHIBITORS | THE UNIVERSITY OF KANSAS (US) | 2015-12-17 | — | — | WO | claimed |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | claimed |
| US-8937077-B2 | Bicyclic diamines as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-01-20 | — | — | US | claimed |
| CN-103664973-A | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2014-03-26 | — | — | CN | claimed |
| US-20130225577-A1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-08-29 | — | — | US | claimed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | claimed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | claimed |
| WO-2007017728-A2 | NOVEL HETEROCYCLIC COMPOUNDS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-02-15 | — | — | WO | claimed |
| US-11992012-B2 | Diaminotriazine compounds | BASF SE (DE) | 2024-05-28 | — | — | US | disclosed |
| CN-113004278-B | Bicyclic heterocycles as FGFR inhibitors | 因赛特控股公司 | 2023-07-21 | — | — | CN | disclosed |
| US-6583141-B1 | T cell mediated rheumatic diseases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-06-24 | — | — | US | disclosed |
| EP-0292800-A2 | Amino acid derivatives | MERCK PATENT GmbH (DE) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11992012-B2 | Diaminotriazine compounds | DDT, DAZAP1, DDC | HDAC8 1947/4885HDAC6 1778/4885HDAC2 394/4885 |
| US-20130225577-A1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | HDAC8 3156/4885HDAC6 1927/4885HDAC2 1190/4885 |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | HDAC8 911/4885HDAC6 301/4885HDAC2 642/4885 |
| US-20170253582-A1 | TRIAZOLE MODIFIED COUMARIN AND BIPHENYL AMIDE-BASED HSP90 INHIBITORS | HSP90AB1, HSP90AB2P, HSP90AA1 | HDAC8 131/4885HDAC6 27/4885HDAC2 89/4885 |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV3, TRPC3, TRPV1 | HDAC8 888/4885HDAC6 281/4885HDAC2 669/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | HDAC8 911/4885HDAC6 301/4885HDAC2 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.